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ABSTRACT
Histone deacetylase inhibitors represent a promising
new class of compounds for the treatment of cancer.
Inhibitors of this kind currently under clinical evalua-
tion mainly target the classical (Rpd3/Hda1) family of
histone deacetylases. Of particular note, the U.S. Food
and Drug Administration recently approved the first
histone deacetylase inhibitor (Zolinza: Merck and Co.,
Whitehouse Station, NJ, U.S.A.) for the treatment of
cutaneous T-cell lymphoma. Dozens of such inhibitors
are now in phase II–III clinical trials, sometimes in
combination with other chemotherapy drugs, for di-
verse cancer types, including both hematologic and
solid tumours. In this mini-review, we provide an over-
view of the histone deacetylase superfamily, highlight
the positive results of deacetylase inhibitors in cancer
clinical trials, and comment on the prospects for the
next generation of such inhibitors.
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1. INTRODUCTION
Aberrations in gene expression patterns lie at the heart
of tumorigenesis. Specifically, inappropriate activa-
tion of oncogenes or silencing of tumour suppressor
genes, or both, drive cellular proliferation and pre-
vent apoptosis 1. Not surprisingly, many proteins in-
volved in regulating transcription are themselves
deregulated in cancer at the level of expression or
activity. One such family of proteins is the histone
deacetylase (HDAC) enzymes. As the name implies,
these enzymes remove acetyl groups from the side
chain of specific lysine residues located mainly at the
N-terminal flexible tails of core histones, thereby in-
creasing the affinity of histone octamers for the DNA
that is wrapped around them (Figure 1). In addition,
deacetylation affects internucleosomal histone–histone
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interactions and association of other proteins with chro-
matin. Because histone deacetylation results in a tight-
ened chromatin structure, histone deacetylation is
generally associated with transcriptional repression 2.
Conversely, acetylation of histones by histone
acetyltransferases relaxes chromatin (or alters its con-
figuration) and leads to activation of transcription. In
this way, HDACs can influence the epigenetic status of
a cell, thereby changing gene expression patterns in
the absence of mutations to the genome itself.
In addition to histones, HDACs target dozens of non-
histone proteins, including many transcription factors
(for example, the tumour suppressor p53), α-tubulin, heat
shock protein 90 (Hsp90: an important anticancer drug
target), and various signalling proteins (Figure 1) 3–5.
Therefore, HDACs not only modulate the structure and
dynamics of chromatin, but also play a key role in regu-
lating other cellular processes such as cell motility,
endocytosis, and membrane receptor signalling. In this
regard, a more appropriate name would be lysine
deacetylases, but for historical reasons, the term HDAC
has been (and is still widely) used even for enzymes
that deacetylate non-histone proteins. Herein, we there-
fore use the term HDAC to refer to lysine deacetylase
enzymes exclusively.
The following five lines of evidence (among oth-
ers) suggest that altered HDAC activity may play a
causative role in both tumorigenesis and metastasis
(Figure 1) 6:
￿ First, histone hypoacetylation is characteristic of
most cancers 7.
￿ Second, in leukemia, HDACs are often aberrantly
recruited to gene promoters by fusion proteins de-
rived from chromosomal translocations 8,9.
￿ Third, overexpression of specific HDACs occurs in
several cancer types, and the growth of cell lines
derived from these tumours is suppressed by small
interfering RNA (siRNA)–mediated knockdown of
the overexpressed HDAC 10.
￿ Fourth, elevated expression of HDACs may block
the function of tumour suppressor proteins such as
p53 11.
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￿ Fifth and finally, in addition to affecting chromatin
structure and regulating gene expression and ge-
nomic stability, HDACs target oncogenic regula-
tors such as Hsp90 that are important for cancer
development 12,13.
With the benefit of hindsight, it is not surprising that
early studies on HDAC inhibitors (HDACIS) revealed their
selective toxicity toward cancer cells, a property that
positioned them as promising anticancer therapeutics.
In the past decade or so, various HDACIs have entered
the clinical trial stage for a variety of cancers 14. In this
mini-review, we provide an overview of the human HDAC
superfamily, describe recent success in clinical trials
for HDACIs, and discuss the potential of class- and isotype-
selective HDACI.
2. THE HDAC SUPERFAMILY
The 18 known human HDACs are grouped into two fami-
lies and four classes that differ from each other in terms
of structure and biologic activity 15,16. The Rpd3/Hda1
FIGURE 1   Schematic of the molecular and physiologic effects of treatment with histone deacetylase (HDAC) enzyme inhibitors (HDACIs). Top panel:
HDACIs prevent the deacetylation of histones by HDACs (left), resulting in an open chromatin structure associated with transcriptional activation
or in non-histone substrates (right), which increases acetylation of these HDAC targets, resulting in changes in protein activity. Middle panel:
Cellular effects of HDACI treatment. Lower panel: Systemic effects of HDACI treatment. HDACI = inhibitor of histone deacetylase; NF-κB = nuclear
factor kappa B; HDAC = histone deacetylase enzymes. Note that although we here highlight the “good side” of HDAC inhibitors, inhibition of HDAC
activity may be detrimental in certain situations and thus give rise to side effects (the “dark side”). And in some cases, activation of HDACs may
even be beneficial. (This figure was kindly produced by Dr. Noriko Uetani at the Rosalind and Morris Goodman Cancer Centre, McGill
University, Montreal, QC. It was inspired by a previous model proposed by others 10.)WALKINSHAW and YANG
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(“classical”) family is composed of class I (HDAC1,
HDAC2, HDAC3, and HDAC8), class IIa (HDAC4, HDAC5,
HDAC7, and HDAC9), class IIb (HDAC 6 and HDAC10),
and class IV (HDAC11). The class III  HDACs (SIRT1
through SIRT7) comprise the sirtuin (Sir2-related pro-
tein) family (Table I). The family names were derived
from the yeast deacetylase prototypes Rpd3 (reduced
potassium dependency 3), Hda1 (histone deacetylase
1), and Sir2 (silent information regulator 2). Within each
family, members display sequence similarity in the
deacetylase domain, but the two families show no ho-
mology at all. In addition, the two families have en-
tirely different catalytic mechanisms and are thus not
targeted by the same inhibitor molecules 17.
The term HDACI is often used to describe com-
pounds that inhibit the classical HDACs of classes I,
II, and IV—compounds to which sirtuins are insensi-
tive (Table I). Owing to their much more advanced
clinical progress, we focus primarily on inhibitors of
Rpd3/Hda1—the “classical” HDACs. Compounds tar-
geting sirtuins are briefly discussed toward the end of
this paper.
Class I HDACs (excluding HDAC8) are subunits of
multi-protein chromatin-modifying complexes 18. Class
IIa HDACs shuttle between the nucleus and the cyto-
plasm in response to extracellular signals; they are
unique among HDACs for apparently weak deacetylase
activity of vertebrate homologs 19–21. The class IIb
member, HDAC6, is found mostly in the cytoplasm,
where it deacetylates cytoskeletal proteins such as α-
tubulin and cortactin 22,23. In sum, the Rpd3/Hda1
HDACs play roles in many cellular processes, includ-
ing proliferation, differentiation, apoptosis, autophagy,
cell motility, and stress responses 16.
3. HDAC INHIBITORS AS ANTICANCER
DRUGS
The HDACIs represent a broad family of chemical com-
pounds that comprises four main structural classes:
￿ Short-chain fatty acids [butyrate and valproic acid
(VPA)]
￿ Hydroxamates [trichostatin A, SAHA (sub-
eroylanilide hydroxamic acid or vorinostat),
LBH589 (panobinostat), PXD101 (belinostat),
oxamflatin, and tubacin]
￿ Benzamides [SNDX275 (MS275) and
MGCD0103]
￿ Cyclic tetrapeptides [FK228 (romidepsin), trapoxin
A, and apicidin]
Not only do these compounds vary in structure, they
also have distinct affinities for various HDACs.
Hydroxamates are the only known pan-HDACIs, with
the ability to target all classical HDACs. In contrast,
butyrate, VPA, and trapoxin A target class I and IIa
HDACs. Other compounds are more specific:
SNDX275 inhibits class I HDACs (but not HDAC8),
romidepsin preferentially targets HDAC1 and HDAC2,
and tubacin selectively inhibits HDAC6 10. The chemi-
cal structures and pharmacokinetic properties of HDACIs
have been extensively reviewed elsewhere 24.
In the late 1970s and then in the early 1990s, a
small number of studies ushered in the era of HDACIs
as chemotherapeutic agents. The HDAC inhibitory ac-
tivity of the naturally occurring compounds butyrate
and trichostatin A (TSA) was found to be responsible
for their ability to cause differentiation and cell cycle
arrest of transformed cells 25,26. Later, chemically syn-
thesized hydroxamates (including SAHA), which were
known to induce differentiation or apoptosis of cancer
cell lines (or both), were also identified as HDACIs 27.
These cell culture results have been recapitulated in
animal models of cancer and in clinical trials with hu-
man cancer patients. Of note, SAHA was approved by
the U.S. Food and Drug Administration in October 2006
under the trade name Zolinza (Merck and Co.,
Whitehouse Station, NJ, U.S.A.), for the treatment of
cutaneous T-cell lymphoma 28. Zolinza and other
HDACIs are achieving successful results in phase II and
III clinical trials for a wide range of cancers 9,10,14,29,
including chronic myelogenous leukemia [panobinostat
(Faridak: Novartis Pharmaceuticals, St. Louis, MO,
U.S.A.)], acute myeloid leukemia (MGCD0103:
MethylGene, Montreal, QC; belinostat: TopoTarget
U.K., Abingdon, U.K.; SNDX275: Bayer Schering
Pharma AG, Berlin, Germany), cutaneous T-cell lym-
phoma (panobinostat; romidepsin: Astellas Pharma,
Tokyo, Japan), B-cell lymphoma (Zolinza, belinostat),
TABLE I   Comparison of the two families of histone deacetylase (HDAC) enzymes
      Member HDAC1–HDAC11 Sirtuin (SIRT1–SIRT7)
       Family Rpd3/Hda1 (“classical”) Sir2 (sirtuin)
Class I, II, and IV III
Cofactor Zn2+ NAD+
Activator ? Resveratrol
Inhibitor Butyrate, TSA, and SAHA Sirtinol, EX-527, and tenovin
Inhibitor for clinical trial Yes Yes
U.S. FDA approval SAHA Not yet
NAD = nicotinamide adenine dinucleotide; TSA = trichostatin A; SAHA = suberoylanilide hydroxamic acid; U.S. FDA = U.S. Food and Drug
Administration.HISTONE DEACETYLASE INHIBITORS FOR CANCER TREATMENT
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breast cancer (Zolinza), prostate cancer (Zolinza,
romidepsin), multiple myeloma (Zolinza, panobinostat,
romidepsin), pancreatic cancer (MGCD0103, romi-
depsin), colorectal cancer (Zolinza), thyroid cancer
(belinostat, romidepsin), non-small-cell lung cancer
[Zolinza; AN9 (a butyrate derivative): Bar-Ilan Re-
search and Development Co., Ramat-Gan, Israel], and
both Hodgkin and non-Hodgkin lymphoma (Zolinza,
panobinostat, belinostat, MGCD0103).
3.1 Mechanism of HDAC Inhibitor-Mediated
Tumour Suppression
Because of the function of HDACs as canonical tran-
scriptional co-repressors, the global transcription
changes elicited by HDACIs are somewhat surprising.
It is estimated that the expression level of approxi-
mately 2%–10% of genes is altered by HDACI treatment,
with as many genes downregulated as upregulated 30.
The most studied of the upregulated genes is CDKN1A,
which encodes the cell cycle inhibitor kinase p21. Al-
though the re-expression of this gene explains the
antiproliferative effect of HDACI, cell-cycle arrest is
not crucial for HDACI-mediated tumour suppression
because HDACIs cause cell-cycle arrest in normal and
cancer cells alike, and unlike many chemotherapeutic
drugs, HDACIs can kill proliferating cancer cells 30.
As for the method of this tumour cell killing, there
are a plethora of routes through which it can occur.
The main process through which HDACIs induce can-
cer cell cytotoxicity is apoptosis (programmed cell
death). Apoptosis can occur through the extrinsic
(death-receptor) or the intrinsic (characterized by cy-
tochrome C release from mitochondria) pathway 30.
Interestingly, the potent pro-apoptotic transcription fac-
tor p53 does not appear to be required for HDACI-in-
duced apoptosis. Instead, the pro-apoptotic Bax and
BH3-only proteins Bid or Bim are necessary for this
effect 31,32. Moreover, overexpression of the anti-
apoptotic proteins Bcl2 or BclXL abrogates apoptosis
induction by HDACI 31.
Apoptosis induced by HDACI also depends on eleva-
tions in reactive oxygen species (ROS) caused by HDACI
treatment. This phenomenon likely reflects the inability
of tumour cells to upregulate thioredoxin, an antioxidant
protein, during HDACI-induced ROS accumulation 33.
The HDACIs can also induce genomic instability
by impairing DNA damage repair 34 and by causing
mitotic catastrophe (mis-segregation of chromosomes
because of defects in the mitotic spindle checkpoint).
Further, in experimental conditions of blocked apoptosis,
HDACIs can still induce cancer cell death by an au-
tophagy-dependent process 35. This latter finding is
exciting, because it indicates that HDACIs may still be
effective against cancers with apoptosis defects 30.
The antitumorigenic properties of HDACIs also ex-
tend to more systemic effects involving the tumour
blood supply, metastatic potential, and host immune
response. The HDACIs inhibit angiogenesis by repressing
the expression of pro-angiogenic factors such as vascu-
lar endothelial growth factor and by reducing the sensi-
tivity of endothelial cells for angiogenic stimuli 10,36. In
addition to preventing the new blood supply crucial to
a growing tumour, HDACIs also inhibit the expression
of matrix metalloproteinase enzymes, which degrade
the basement membrane surrounding tumours, an im-
portant initial step in metastasis 10. Moreover, stimu-
lation of the host immune response by HDACIs can
sensitize tumour cells for destruction by the immune
system 37. Therefore, HDACIs can induce diverse cel-
lular and physiologic processes that act in concert to
prevent the initiation and progression of cancer.
3.2 Potential of Isotype- or Class-Selective HDAC
Inhibitors
The fact that class I-selective HDACIs (for example,
MGCD0103, SNDX275, and romidepsin) possess
antitumorigenic capacities strongly suggests that inhi-
bition of class I HDACs may be sufficient for chemo-
therapy. In support of this hypothesis, genetic deletion
and siRNA-mediated knockdown studies support the
non-redundant role of these HDACs in controlling cell
proliferation and survival 6. In particular, HDAC1
knockout mice die during embryogenesis because of a
lack of cell proliferation 38; gene trap–mediated dis-
ruption of HDAC2 reduces tumour growth in a tumour-
prone mouse model 39; and loss of HDAC3 causes
embryonic lethality associated with decreased prolif-
eration, DNA damage, and apoptosis 34. Moreover,
overexpression of each of these HDACs is seen in sev-
eral cancer types 6.
In addition to these class I HDACs, the class IIb
member HDAC6 is likely also an important target of
HDACI-mediated cancer suppression because of its
ability to control cell migration through deacetylation
of α-tubulin and cortactin, and through its ability to
deacetylate Hsp90 and to disrupt that protein’s func-
tion as a chaperone for oncogene products 6.
In contrast, there is much less evidence implicat-
ing class IIa HDACs in tumorigenesis. In fact, inhibi-
tion of class IIa HDACs (as occurs during treatment
with pan-HDACIs such as vorinostat, TSA, VPA, or bu-
tyrate) could lead to a host of unwanted side effects,
as inferred from the role of class IIa HDACs in limiting
the activation of myocyte enhancer factor 2 (Mef2) tar-
get genes. Genetic deletion of each class IIa member
causes unrestrained MEF2 activation, leading to skel-
etal defects, pathologic cardiac hypertrophy, or collapse
of the vascular system 40. Thus, it will be of interest to
compare long-term recipients of class I-selective
HDACIs with recipients of pan-HDACIs to see if pa-
tients in the latter group selectively suffer from these
types of side effects.
Although it has not yet been established whether
class I–selective HDACIs elicit fewer side effects than
pan-HDACIs do, it is clear that HDACIs in general are
associated with certain toxicities, including fatigue,WALKINSHAW and YANG
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nausea, diarrhea, and vomiting 9,41. The issue of
HDACI toxicity must be addressed if drugs with a broad
range of clinical utilities in diverse patients are to be
developed. Currently, only one truly specific HDACI
has been developed. Tubacin selectively targets
HDAC6, and it can induce apoptosis of multiple my-
eloma cells in vitro 42 and inhibit transforming growth
factor β–induced epithelial-to-mesenchymal transi-
tion 43. However, this compound has yet to enter clini-
cal trials, and thus its toxicity profile is not yet known.
Of course, whether isotype-selective HDACIs will re-
duce toxic side effects will remain unknown until such
agents are developed and tested. Yet, even if the next
generation of HDACIs lack better toxicity profiles, they
will nevertheless be instrumental in elucidating the
function or functions of individual HDACs involved in
various types and stages of cancer and in other human
diseases.
The specific HDACI used for specific cases may
also be of critical importance independent of the HDACs
it inhibits. A recent study demonstrated that specific
HDACIs can have dramatically different effects depend-
ing on the molecular profile of the tumour. In a mouse
model of B cell lymphoma, Bcl2 overexpression blocks
the ability of the hydroxamates, but not of the cyclic
tetrapeptide romidepsin to prevent lymphoma 44.
Whether this differential blocking is the result of dif-
ferent substrate specificities is unknown, but it at least
points to the phenomenon that not all HDACIs are equal
in terms of biologic activity. This result also provides a
glimpse into a future, when therapies are tailored to
the individual gene expression profiles of tumours in
patients 45. In this case, a lymphoma patient with
overexpressed Bcl2 would be better served with
romidepsin than with a hydroxamate HDACI.
3.3 Use of HDAC Inhibitor in Combination with
Other Chemotherapies
The optimal use of HDACIs is highly likely to be in
combination with other anticancer therapies. Several
studies have shown that HDACIs can synergize with a
large set of other chemotherapeutic drugs such as
cisplatin, etoposide, bortezomib, and gemcitabine.
Other therapeutics that exhibit an additive or synergistic
effect when used with HDACIs include differentiation
agents such as retinoic acid (RA) and all-trans retinoic
acid (ATRA) for the treatment of leukemic cells;
imatinib, an inhibitor of the Bcr-Abl tyrosine kinase
expressed by the Philadelphia chromosome in chronic
myelogenous leukemia; the breast cancer drug
trastuzumab, a monoclonal antibody against the HER2/
neu (ErbB2) receptor; and 17AAG, an inhibitor of the
oncogenic protein chaperone Hsp90 10,30. In all these
cases, at least in vitro, these drugs cooperate with
HDACIs to enhance apoptosis—or, in the case of RA
and ATRA, differentiation—of cancer cells. Further,
HDACIs can induce differentiation or apoptosis, respec-
tively, of RA- or imatinib-resistant cells. In addition,
HDACIs enhance the radiosensitivity of gamma- or ul-
traviolet-irradiated tumours and can bolster the effect
of the TRAIL (tumour necrosis factor–related apoptosis-
inducing ligand) death receptor ligand on tumour cell
death 10,30. A link is emerging between HDAC activity
and DNA methylation in controlling gene expression 18;
it is therefore not surprising that the combination of
HDACIs and DNA methyltransferase inhibitors also ex-
hibit enhanced anti-neoplastic activity 10,30.
Excitingly, it appears that the principle of synergism
between HDACIs and other compounds can be reca-
pitulated in a single hybrid compound. The first com-
pound of this kind, termed triciferol, in which the side
chain of 1,25-vitamin D3 (the active form) is replaced
with the dienyl hydroxamic acid of TSA 46, possesses
characteristics of both 1,25-D3 (vitamin D receptor
agonism) and TSA (histone hyperacetylation) and ex-
hibits effects similar to co-treatment with the two origi-
nal compounds in terms of cancer cell cytotoxicity in
vitro 46,47. It will be greatly interesting to see if this
compound is effective in animal studies and human
clinical trials, and also to see whether HDACIs can be
combined with other drugs to form new antitumorigenic
hybrid compounds.
4. SUMMARY AND FUTURE PERSPECTIVES
The flurry of activity surrounding the development of
HDACIs has paralleled the rapid expansion over the past
decade of research into the molecular details of HDAC
activity and the biologic roles of these enzymes. The
discovery of their importance to multiple stages of tu-
mour initiation and progression provided a strong ra-
tionale for the use of compounds targeting these
epigenetic regulators in cancer treatment. With cur-
rent compounds exhibiting positive clinical results, and
one HDACI already on the market in the United States,
it is clear that HDACIs will likely represent an impor-
tant class of chemotherapeutic drugs in the near fu-
ture. Whether newer HDACIs, possibly isotype-selective
versions, will ultimately supplant the current collec-
tion remains to be seen, but would not be surprising
given the modest toxicity problems associated with
today’s generation of HDACIs. Nevertheless, the clini-
cal utility of altering HDAC activity has been unam-
biguously demonstrated.
Although we have focused on inhibitors of the Rpd3/
Hda1 family of deacetylases herein, modulators of
sirtuin activity (Table I) may prove to be important
therapeutics for the treatment of various diseases, in-
cluding cancer 48. For instance, the SIRT1 activator
resveratrol—a polyphenol famously contained in red
wine—can prevent cancer by targeting multiple stages
of progression in mice 49. In addition, it was recently
reported that tenovins, novel SIRT1 and SIRT2 inhibi-
tors, increase apoptosis of cancer cell lines and delay
tumour growth in mice, in part by increasing the acetyla-
tion and transcriptional activity of TP53 50. Despite these
advances, sirtuin-targeting compounds (inhibitors andHISTONE DEACETYLASE INHIBITORS FOR CANCER TREATMENT
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activators alike) lag behind conventional HDACIs in
terms of their progression from the lab to the phar-
macy. Their continued development, alongside that of
HDACIs, is crucial to fully exploit the importance of
protein acetylation in cancer.
The present mini-review has dealt primarily with
the idea that increasing acetylation of histones or other
proteins through HDAC inhibition is always desirable,
but it is important to note that it is the balance of HDAC
and histone acetyltransferase activities, and hence the
relative acetylation levels of key proteins (which may
vary in different tissues and disease states) that is of
ultimate importance. For this reason, cases may occur
in which too much acetylation is pathologic, and in-
hibitors of histone acetyltransferases may therefore be
efficacious 51,52. Indeed, inhibition of the acetyltrans-
ferase activity of p300 by curcumin—the polyphenol
contained in the curry spice turmeric—blocks cardiac
hypertrophy and heart failure in mouse models 53.
Curcumin has also been touted as a potential antican-
cer compound, although it is not yet known whether its
potential activity is a function of its histone acetyltrans-
ferase inhibitory function 54.
Although cancer has traditionally been viewed as
a genetic disease, the perspective of cancer as an epige-
netic disease is rapidly emerging. Thus, in addition to
mutations in the DNA code, it is increasingly clear
that cancer can result from aberrations in chromatin
and chromatin-modifying proteins such as HDACs. As
a result, HDACIs represent one promising subgroup of
compounds for epigenetic therapy. The elucidation of
the mechanisms through which HDACIs suppress tu-
mours, the discovery of the particular HDACs that are
involved in each stage or type of cancer, the contin-
ued development of isotype-selective HDACIs, and the
optimization of HDACIs as a component of combina-
tion chemotherapy represent important breakthroughs
that will undoubtedly occur in the near future. With
continued research and development, HDACIs are
likely to figure prominently in cancer treatment plans
in the near future.
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